A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
12/2006
12/14/2006	WO2006132438A1 1,3-benzothiazinone derivative and use thereof
12/14/2006	WO2006132341A1 sc(Fv)2 SITE-DIRECTED MUTANT
12/14/2006	WO2006132217A1 Crystal of salt of benzimidazole compound
12/14/2006	WO2006131586A1 Bioactive peptides identified in enzymatic hydrolyzates of milk caseins and method of obtaining same
12/14/2006	WO2006131519A1 Quinoline derivatives as antibacterial agents
12/14/2006	WO2006131340A2 Pyrrolones that act as peptide deformylase (pdf) inhibitors
12/14/2006	WO2006131303A2 Peptide deformylase (pdf) inhibitors 4
12/14/2006	WO2006131186A1 Oxindoles as kinase inhibitors
12/14/2006	WO2006130974A1 Hyaluronic acid binding peptides enhance host defense against pathogenic bacteria
12/14/2006	WO2006109071A3 Vaccine against burkholderia infections
12/14/2006	WO2006078925A3 A tetracycline metal complex in a solid dosage form
12/14/2006	WO2006078274A3 Beta-peptides
12/14/2006	WO2006074409A9 Tripeptide and tetrapeptide sulfones
12/14/2006	WO2006072636A3 1, 5, 6-substituted-2-oxo-3-cyano-1, 6a-diaza-tetrahydro-fluoranthenes as anti-infective agents
12/14/2006	WO2006017505A3 Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases
12/14/2006	WO2005112648A8 Sulphur-containing oils for controlling plant pathogens and stimulating nutrient uptake
12/14/2006	WO2005074986A3 Bioactive species capable of interfering with a microbial toxin-antitoxin complex and methods for evaluation and use of said bioactive species
12/14/2006	WO2001022972A9 Immunostimulatory nucleic acids
12/14/2006	US20060282908 Identification of the genetic determinants of the polymorphic CYP3A5 expression
12/14/2006	US20060281926 Synthesis of 2-alkylcysteine via phase transfer catalysis
12/14/2006	US20060281905 Crystallization of IGF-1
12/14/2006	US20060281902 Human signal peptide-containing proteins
12/14/2006	US20060281887 (Meth)acrylate copolymer for use as medical carrier
12/14/2006	US20060281804 N-Benzyl-2,3,4,9-tetrahydrocarbazole-1-amine hydrochloride salt, for the treatment of human papillomaviruses infection, genital warts, or cervical dysplasia
12/14/2006	US20060281779 1 -cyclopropyl-7- [3-cyclopropylaminomethyl-4-fluoro-1 -pyrrolidinyl]-6-fluoro -1 ,4-dihydro-8-methyl-4-oxo-3-quinolinecarboxylic acid; bactericide; against drug-resistant bacteria and against gram-positive bacteria, such as MRSA, PRSP and VRE
12/14/2006	US20060281761 Osteoporosis; oral diseases; bone disorders; atherosclerosis; antiarthritic agents; autoimmune disease; cachexia
12/14/2006	US20060281742 Amines that inhibit a mammalian anandamide transporter, and methods of use thereof
12/14/2006	US20060281734 3-[5-(3-acetamidobenzamido)-2-methylphenyl]-6-(4-methylpiperazin-1-yl)-3,4-dihydroquinazolin-4-one for example; treating rheumatoid arthritis, osteoarthritis, psoriasis, chronic obstructive pulmonary disease; inhibitor of cytokine-mediated disease
12/14/2006	US20060281719 Oestrogen-17-sulphamates as inhibitors of steroid sulphatase
12/14/2006	US20060281706 New phosphonate ester derivatives of drugs such as antivirals cidofovir, adefovir, tenofovir, azidothymidine (AZT), or bisphosphonates such as alendronate, or anticancers such as cytosine arabinoside; side effect reduction, less toxic; antiviral
12/14/2006	US20060281704 Regulation of endogenous gene expression in cells using zinc finger proteins
12/14/2006	US20060281152 Glycosaminoglycans derived from the K5 polysaccharide having high anticoagulant and antithrombotic activity and process for their preparation
12/14/2006	US20060281072 Stimulation of human T-cells and used to enhance antigen-specific immune responses; immunotherapy
12/14/2006	US20060280771 Drug delivery system
12/14/2006	US20060280756 Novel composition
12/14/2006	US20060280751 Method for enhancing efficacy of preparation of monoclonal antibody
12/14/2006	US20060280750 Anti-idiotypic antibodies which recognise the idiotope of an antibody specific for a yeast killer toxin possess microbicidal activity
12/14/2006	US20060280745 Prion inhibition
12/14/2006	US20060280723 Interferon for treating or preventing a coronaviral infection
12/14/2006	US20060280692 A condensation aerosol for delivery of olanzapine by heating a compositionof olanzapine coated on a solid support to vaporize and condense; the vapor comprising particles of >10 percent by weight of olanzapine and <5 percent by weight of olanzapine degradation products; aerodynamic diameter=<5 microns
12/14/2006	DE202006012037U1 Foot towel comprises a base member with an active material surface, and a support surface
12/14/2006	CA2611416A1 Bioactive peptides identified in enzymatic hydrolyzates of milk caseins and method for the production thereof
12/14/2006	CA2611401A1 Oxindoles as kinase inhibitors
12/14/2006	CA2611261A1 Crystal of salt of benzimidazole compound
12/14/2006	CA2610976A1 Use of stefin a as a scaffold protein
12/14/2006	CA2610791A1 Hyaluronic acid binding peptides enhance host defense against pathogenic bacteria
12/14/2006	CA2610771A1 Anti-trkb monoclonal antibodies and uses thereof
12/14/2006	CA2610304A1 Peptide deformylase (pdf) inhibitors 4
12/14/2006	CA2601202A1 New hybrid oligomers. their preparation process and pharmaceutical compositions containing them
12/13/2006	EP1731531A2 Multiple cytokine-antibody complexes
12/13/2006	EP1731506A1 5-hydroxyindole-3-carboxylates derivatives and their use
12/13/2006	EP1731168A1 Antibody drug
12/13/2006	EP1731167A1 Vaccine against hbv and hpv
12/13/2006	EP1731166A2 Streptococcus pneumoniae proteins and vaccines
12/13/2006	EP1731159A1 Method of preventing nodavirus infection and therapeutic method
12/13/2006	EP1731155A2 Beta-D-2', 3' -Didehydro-2',3' -Dideoxy-5-Fluorocydine for use in the treatment of HIV infections
12/13/2006	EP1730282A1 Glycosylation variants of ricin-like proteins
12/13/2006	EP1730197A2 Methods for inducing autolysis in infectious bacteria
12/13/2006	EP1730180A1 Antifungal peptides
12/13/2006	EP1730178A2 Novel antibiotic alternatives
12/13/2006	EP1730176A2 Mvl, an antiviral protein from a cyanobacterium
12/13/2006	EP1730167A1 Macrocyclic peptides active against the hepatitis c virus
12/13/2006	EP1730163A1 Pharmaceuticals salts of 3-o-(3,3-dimethylsuccinyl) betulinic acid
12/13/2006	EP1730142A1 Novel ketoamides with cyclic p4's as inhibitors of ns3 serine protease of hepatitis c virus
12/13/2006	EP1730135A1 Qiunolin-4-ones as inhibitors of retroviral integrase for the treatment of hiv, aids and aids related complex (arc)
12/13/2006	EP1730120A1 Non-nucleoside reverse transcriptase inhibitors
12/13/2006	EP1730116A1 4-carbox pyrazole derivates useful as anti-viral agents
12/13/2006	EP1730110A1 Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease
12/13/2006	EP1729782A2 Treatment and prophylaxis of sepsis and septic shock
12/13/2006	EP1729747A2 Thiol reactive agents as a therapeutic modality
12/13/2006	EP1404853B1 Process for the production of allicin
12/13/2006	EP1343896B1 Small acid-soluble spore protein and uses thereof
12/13/2006	EP1326599B1 Use of aivlosin for treating or preventing Lawsonia infections in pigs.
12/13/2006	EP1261712B1 Proteins named fctrx and nucleic acids encoding same
12/13/2006	EP1179067B1 Neuroprotective properties of gdf-15, a member of the tgf-beta superfamily
12/13/2006	EP1140156B1 Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
12/13/2006	EP1123392B1 Prv-1 gene and the use thereof
12/13/2006	EP1024836B1 Compositions for delivering genes to antigen presenting cells of the skin
12/13/2006	EP0875251B1 Therapeutic agent for treatment of fiv infections
12/13/2006	EP0809695B1 Transcription factor - e2f-5
12/13/2006	EP0678035B9 Vaccine preparations
12/13/2006	EP0651805B1 Method of intracellular binding of target molecules
12/13/2006	CN1878824A Tri-block copolymers and a process for the preparation of the same
12/13/2006	CN1878777A 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis
12/13/2006	CN1878767A Azole-based kinase inhibitors
12/13/2006	CN1876833A Anti-hiv agent evaluation method
12/13/2006	CN1876683A Human antibodies that bind human TNFalpha
12/13/2006	CN1876679A Compounds from moraxella catarrhalis
12/13/2006	CN1876678A Retroviral resistant polypeptide and its preparing method
12/13/2006	CN1876672A Steroid imidazole salt compound and its preparing process
12/13/2006	CN1876184A Formulation for treating disease infected by helicobacter pylori
12/13/2006	CN1876181A Weak toxicity united vaccine formulation for canidae animal important disease series and preparation process
12/13/2006	CN1876180A Use of protein TolC in preparing immunological formulation and vaccine
12/13/2006	CN1876179A Use of protein YaeT in preparing immunological formulation and vaccine
12/13/2006	CN1876174A Pharmaceutical combination containing kuhseng element and thymus pentapeptide and preparation method thereof
12/13/2006	CN1876173A Thymus pentapeptide slow-release microshpere formulation for injection and its preparation method
12/13/2006	CN1876151A A pharmaceutical composition for treating cold, its preparation method and use
12/13/2006	CN1876144A A Chinese medicine for treating skin disease of fur-bearing animal and preparation process thereof
12/13/2006	CN1876103A Modified 'Shuang Huanglian' medicinal liquor for birds and preparation method thereof
12/13/2006	CN1876077A A medicament for treating superficial lymphoid tuberculosis

1 ... 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 ... 1798